# US 2022/0031611 A1 · Immunosuppressive dosage forms and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031611 A1
- Document ID: US20220031611A1
- Status: Published application
- Kind: A1
- Application number: 17/506,748
- Filed: 2021-10-21
- Published: 2022-02-03
- Earliest claimed: 2018-03-19
- Assignees: Gemini Laboratories, LLC
- Applicants: Gemini Laboratories, LLC
- Inventors: Padam Bansal; Hardik Patel; Amitkumar Patel; Suhaskumar Patel
- Web page: https://patentgrep.com/patent/US20220031611A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to formulations, methods, kits, and dosage forms for oral pharmaceutical formulations comprising one or more immunosuppressive agents. The pharmaceutical formulations of the present disclosure can be useful in treating organ or stem cell transplant recipients or T-cell mediated diseases.

## Claims

### Claim 1

An oral liquid dosage formulation comprising:
(a) one or more immunosuppressive agents;
(b) one or more pharmaceutically acceptable solubilizers; and
(c) optionally one or more pharmaceutically acceptable excipients selected from the group consisting of flavoring agents, sweeteners, preservatives, buffering agents, pH adjusting agents, dispersants, carriers or combinations thereof wherein the formulation is a non-aqueous solution.

### Claim 2 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the one or more immunosuppressive agent is selected from the group consisting of cyclosporine, tacrolimus, sirolimus, everolimus and combinations thereof.

### Claim 3 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the one or more pharmaceutically acceptable solubilizers are selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, ethanol, polysorbates, oils and combinations thereof.

### Claim 4 (depends on 3)

The oral liquid dosage formulation of claim 3 wherein the one or more pharmaceutically acceptable solubilizers are selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, oils and combinations thereof.

### Claim 5 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the one or more pharmaceutically acceptable solubilizers are liquid at room temperature.

### Claim 6 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the formulation is substantially free of a surfactant, wetting agent or emulsifying agent.

### Claim 7 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the formulation is substantially free of low molecular weight mono alcohols.

### Claim 8 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the concentration of the one or more immunosuppressive agents is about 0.1 mg/mL to about 1.5 mg/mL.

### Claim 9 (depends on 1)

The oral liquid dosage formulation of claim 1 wherein the concentration of the one or more immunosuppressive agents is about 0.5 mg/mL to about 1.0 mg/mL.

### Claim 10

An oral liquid dosage formulation comprising:
(a) tacrolimus;
(b) one or more pharmaceutically acceptable solubilizers selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, ethanol, polysorbates, oils and combinations thereof; and
(c) optionally one or more pharmaceutically acceptable excipients selected from the group consisting of flavoring agents, sweeteners, preservatives, buffering agents, pH adjusting agents, or combinations thereof wherein the formulation is a non-aqueous solution, free of a surfactant, wetting agent, emulsifying agent and low molecular weight mono alcohols.

### Claim 11 (depends on 10)

The oral liquid dosage formulation of claim 10 wherein the concentration of the tacrolimus is about 0.1 mg/mL to about 1.5 mg/mL.

### Claim 12 (depends on 10)

The oral liquid dosage formulation of claim 10 wherein the concentration of the tacrolimus is about 0.5 mg/mL to about 1.0 mg/mL.
